IL17A and rheumatoid arthritis: These effects lead to osteoclastogenesis and ultimately bone resorption in RA; however, OPG and infliximab (anti-TNF-α monoclonal antibody (mab)) can inhibit the effect of IL-17 on osteoclastogenesis [82].